High-Purity Research Compounds | Trusted Quality & Consistency
For Laboratory & Scientific Research Use Only
Worldwide Shipping | Secure Packaging | Cold-Chain Storage
Explore Products

High-Purity Research Compounds | Trusted Quality & Consistency
Request Recommendation

RETATRUTIDE 20mg

RETATRUTIDE 20mg
RETATRUTIDE 20mg - Image 2
View Lab Certificate
Download Lab Certificate

RETATRUTIDE 20mg

£179.00

Retatrutide is a triple hormone receptor agonist. While current weight-loss drugs like Wegovy (GLP-1 only) or Mounjaro (GLP-1 and GIP) target one or two pathways, Retatrutide activates three specific metabolic receptors:

  1. GLP-1 (Glucagon-like peptide-1): Slows gastric emptying and signals the brain to reduce appetite.

  2. GIP (Glucose-dependent insulinotropic polypeptide): Enhances insulin secretion and improves how the body breaks down fat.

  3. GCG (Glucagon): Increases energy expenditure (calorie burning) and specifically targets fat stored in the liver.

    Because it targets these three pathways simultaneously, it is often referred to in medical circles as “Triple G.” In clinical trials, it has shown the potential for significant weight loss (up to 24% of body weight over 48 weeks) and substantial improvements in blood sugar and liver fat levels.
Categories , ,

(Triple-action peptide)

Retatrutide (also known by the developmental code LY3437943) is an experimental “triple agonist” peptide being developed by Eli Lilly and Company. It is considered a potential successor to medications like Tirzepatide (Mounjaro/Zepbound) due to its broader mechanism of action.

Product Specifications

  • Chemical Name: Retatrutide

  • CAS Number: 2381089-83-2

  • Molecular Formula: $C_{221}H_{342}N_{46}O_{68}$

  • Molecular Weight: Approximately 4731.42 g/mol

  • Format: Typically supplied as a lyophilized (freeze-dried) powder in various strengths (e.g., 5mg, 10mg, or 20mg vials) for reconstitution.

Status and Usage

  • Current Phase: As of early 2026, Retatrutide is in Phase 3 clinical trials. It is not yet FDA-approved for general public use.

  • Application: It is designed as a once-weekly subcutaneous injection.

  • Research Focus: It is being studied primarily for the treatment of obesity, type 2 diabetes, and fatty liver disease (MASH/MASLD).

    [!IMPORTANT] Since Retatrutide is still in the clinical trial phase, a “20mg” product is often found in research settings or via peptide suppliers. It should only be used under strict medical supervision or within authorized clinical studies.

Related products